… regarding the use of semaglutide in obesity-related HFpEF. First, the 2 available trials were
underpowered to examine the effects of semaglutide on hard CV outcomes and mortality. …

… semaglutide is efficacious for sustained weight loss among individuals with overweight/obesity
and without diabetes. … Semaglutide and Cardiovascular Outcomes in Patients with Type 2 …

… obesity [(10)], leading to its approval for the treatment of obesity in individuals with or without
diabetes … However, the efficacy of semaglutide in patients with a body mass index (BMI) ≥ …

… aimed to provide a more definitive assessment of the effects of semaglutide across a range
of outcomes and to test whether these effects were consistent across key patient subgroups. …

… semaglutide (2.4 mg) in participants living with obesity either with and without diabetes or
pre-diabetes … To date, the cardioprotective effects of GLP-1a in obesity were derived from RCT …

… with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 trial was a randomized, …
, CV outcomes trial evaluating the CV safety of once-weekly subcutaneous semaglutide at two …

… However, few participants used obesity pharmacotherapy so our findings were not … not
using obesity pharmacotherapy. In addition, all analyses were exploratory and thus no formal …

… on semaglutide as the first antiobesity drug shown to decrease CV events in subjects with
obesity and prevalent CV … The mechanisms whereby semaglutide decreased CV outcomes are …

… two large cardiovascular outcome trials of liraglutide (LEADER)7 and semaglutide (SUSTAIN
6… GLP-1 analogues compared with placebo on the primary outcome of MACE (HR [95% CI]: …

… risk reduction with liraglutide, subcutaneous semaglutide, albiglutide, and dulaglutide …
placebo in the Harmony Outcomes trial (15); in the remaining trials, no significant differences in …